Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$7.74
-4.3%
$7.96
$5.37
$17.58
$501.72M1.791.20 million shs566,961 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$34.91
+3.8%
$41.32
$14.78
$48.53
$2.11B0.291.11 million shs565,687 shs
Immunome, Inc. stock logo
IMNM
Immunome
$18.23
-2.0%
$21.97
$7.96
$27.65
$2.06B2.041.35 million shs314,888 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$67.01
-4.3%
$57.61
$23.30
$80.50
$4.18B2.231.38 million shs775,246 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-1.10%-11.60%-9.93%+28.07%+6.67%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-3.11%-10.34%-17.47%+11.21%+62.15%
Immunome, Inc. stock logo
IMNM
Immunome
+0.16%-10.44%-17.07%-14.87%+103.83%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+1.18%+3.21%+23.20%+54.27%+121.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$7.74
-4.3%
$7.96
$5.37
$17.58
$501.72M1.791.20 million shs566,961 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$34.91
+3.8%
$41.32
$14.78
$48.53
$2.11B0.291.11 million shs565,687 shs
Immunome, Inc. stock logo
IMNM
Immunome
$18.23
-2.0%
$21.97
$7.96
$27.65
$2.06B2.041.35 million shs314,888 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$67.01
-4.3%
$57.61
$23.30
$80.50
$4.18B2.231.38 million shs775,246 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-1.10%-11.60%-9.93%+28.07%+6.67%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-3.11%-10.34%-17.47%+11.21%+62.15%
Immunome, Inc. stock logo
IMNM
Immunome
+0.16%-10.44%-17.07%-14.87%+103.83%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+1.18%+3.21%+23.20%+54.27%+121.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.67
Reduce$8.509.83% Upside
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.86
Moderate Buy$61.5076.16% Upside
Immunome, Inc. stock logo
IMNM
Immunome
2.85
Moderate Buy$33.1781.94% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$58.00-13.44% Downside

Current Analyst Ratings Breakdown

Latest DNA, TWST, ELVN, and IMNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Initiated CoverageBuy$60.00
6/2/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Boost Price TargetOutperform$45.00 ➝ $62.00
5/28/2026
Immunome, Inc. stock logo
IMNM
Immunome
Boost Price TargetBuy$36.00 ➝ $37.00
5/28/2026
Immunome, Inc. stock logo
IMNM
Immunome
Initiated CoverageOverweight$36.00
5/28/2026
Immunome, Inc. stock logo
IMNM
Immunome
Initiated CoverageOverweight$36.00
5/22/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$80.00
5/15/2026
Immunome, Inc. stock logo
IMNM
Immunome
Lower Price TargetOutperform$37.00 ➝ $33.00
5/13/2026
Immunome, Inc. stock logo
IMNM
Immunome
Reiterated RatingBuy$40.00
5/12/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Initiated CoverageBuy$80.00
5/11/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
UpgradeStrong-Buy
5/8/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Boost Price TargetBuy$41.00 ➝ $59.00
(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$170.15M2.97N/AN/A$8.74 per share0.89
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$7.74 per shareN/A
Immunome, Inc. stock logo
IMNM
Immunome
$6.94M297.47N/AN/A$5.75 per share3.17
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M11.08N/AN/A$7.84 per share8.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)
Immunome, Inc. stock logo
IMNM
Immunome
-$212.39M-$2.38N/AN/AN/AN/A-51.15%-47.32%8/5/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)

Latest DNA, TWST, ELVN, and IMNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
Immunome, Inc. stock logo
IMNM
Immunome
-$0.60-$0.48+$0.12-$0.48$0.22 millionN/A
5/7/2026Q1 2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.44-$0.38+$0.06-$0.38N/AN/A
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
5.15
5.15
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
40.32
40.32
Immunome, Inc. stock logo
IMNM
Immunome
N/A
21.68
21.68
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42

Institutional Ownership

CompanyInstitutional Ownership
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
12.69%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00%
Immunome, Inc. stock logo
IMNM
Immunome
7.21%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64065.32 million57.03 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5060.90 million59.08 millionOptionable
Immunome, Inc. stock logo
IMNM
Immunome
40113.25 million105.09 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$7.74 -0.35 (-4.34%)
As of 12:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$34.91 +1.28 (+3.81%)
As of 12:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Immunome stock logo

Immunome NASDAQ:IMNM

$18.23 -0.38 (-2.05%)
As of 12:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$67.01 -3.03 (-4.33%)
As of 12:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.